XYLEM

Xylem reported third-quarter revenue of $2.20 billion (expectation $2.28 billion) and adjusted EBITDA of $527 million (expectation $544 million). Adjusted earnings per share were $1.44 versus an expected $1.45. Because of the results, the company scrapped its growth expectation and lowered the annual forecast to $5.40–$5.45 earnings per share and revenue of around $8.95 billion; the stock fell nearly 13% and below the $100 mark. » More on deraktionaer.de

Xylem confirmed the unexpected exit of finance chief William “Bill” Grogan, who is taking a CFO role at GE HealthCare. Andrea van der Berg will succeed him on September 1, 2026; Grogan is expected to remain until mid-September to hand over. The stock fell about 3.4% intraday to $112.50, even though Xylem left its quarterly and full-year guidance unchanged. Markets reacted sensitively to the leadership change against the backdrop of rising US yields, higher oil prices and geopolitical risks, adding further uncertainty to strategic execution. » More on de.investing.com

Xylem has signed a definitive acquisition agreement through a subsidiary to acquire WaterFleet for roughly $200 million. WaterFleet provides mobile drinking water and wastewater treatment as well as water-quality monitoring for remote, temporary and infrastructure-sensitive sites. The company is being sold by investment funds managed by EagleTree Capital; the closing remains subject to customary conditions and regulatory approvals and is expected to occur this quarter. » More on de.investing.com

Xylem has completed the sale of its Sensus business outside North America to AURELIUS, but for strategic reasons is retaining the Sensus business in North America. The stock is trading near its 52‑week low, while an InvestingPro analysis rates the company as undervalued at the current level. Xylem employs around 22,000 people, has a market capitalization of about $26.3 billion and annual revenue of $9.1 billion; the dividend has been raised for 15 consecutive years. » More on de.investing.com

Xylem shares fell to a new 52-week low of $114.15 and are down 6.97% over the past 12 months; the stock lost about 23% in the last six months and 15% year-to-date. InvestingPro rates the stock as undervalued and praises its financial health, while 12 analysts have cut their earnings estimates. In Q1 2026, Xylem beat EPS expectations with $1.12, slightly missed revenue at $2.1 billion, but raised full-year revenue guidance to +2–3%, which was received positively by the market. » More on de.investing.com